In this episode, we sat down with Antony Odell (https://www.linkedin.com/in/antonyrodell/), co-founder and CEO of Echopoint Medical (https://www.echopointmedical.com/). Echopoint is a London-based UCL spinout developing iKOr, an optical microcathet...
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
[upbeat music] We had a wonderful box with wires coming out of it, which was our first console [laughs] in UCL, which looked like something from the Frankenstein's lab. You know, when you move that into an environment where you're, you know, testing it rigorously, you're providing, you know, with, you know, you're looking for ground truth, things change. You know, you find things out that weren't important to the academic. And, you know, the IP that we got from the university was, was good basic ground IP and we've got grant patents in that space, but, you know, we've had to really translate that into something that is reproducible and you can make at a reasonable price and produces clinically meaningful data.
[upbeat music] Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology. Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey, everyone. In this episode of MedSider, we sat down with Anthony O'Dell, co-founder and CEO of EchoPoint Medical. EchoPoint is a London-based UCL spinout developing the iCor, an optical microcatheter for coronary diagnostics.
Anthony brings over 30 years of med tech experience across Johnson & Johnson, Fresenius, and Stryker before transitioning into startups as CEO of TeiSide Flow Technologies and Tissue Regenix. He holds a BSc in physiology and biochemistry. Here are a few topics we explored in this conversation. First, what does it take to translate academic IP into a fundable company? Second, how should you choose clinical sites when speed comes with the trade-off of learning? Third, when does a grant become a liability instead of an asset? And last, what are the CEO's responsibilities that determine early-stage outcomes?
Before we dive into the full episode, if you're a med tech founder or CEO preparing to raise capital, you should check out the MedSider Fundraising Cohort. This four-week live workshop combines small group sessions with real-time feedback to help you sharpen your investor story, build a targeted investor pipeline, and run a focused fundraising sprint instead of a never-ending slog. Over the month, you'll walk away with an investor-ready narrative and deck, outreach scripts that actually get responses, a refreshed LinkedIn profile, a simple content plan that keeps you on investors' radar, and a repeatable system for running your raise.
You can join the wait list at medsider.com/fundraisingcohort. Again, that's medsider.com/fundraisingcohort. All right, let's get to the interview. [upbeat music] All right, Anthony, welcome to, uh, MedSider Radio. Appreciate you coming on. Thanks very much for the invitation, Scott. It's been, uh, it's gonna be fun, I hope. I think it's gonna be fun. Hopefully a little bit, uh, hopefully mostly fun, right? But, uh, but also we'll mix in some, uh, hopefully some ed- some educational stuff for the folks listening that they can, uh, take away to their own, their own startups or maybe if they're at the, at a strategic, maybe their own business inside, uh, inside the multinational.
But with that said, I recorded a very short bio at the outset of this interview, but let, I always like to kinda start here. Give us a, like a one-minute overview of your, your career leading up to taking on, uh, the CEO role at, at EchoPoint. Yeah, I mean, without giving you the CV, I think I've always been interested in clinical insight and how that translates into commercial reality, and I had what you might call a fairly standard career out of corporate. [laughs] So usual suspects, J&J, Fresenius, Stryker, blah, blah, blah. But I've, I've always been in that kind of space where I'm looking at, you know, how do you take a, a, a really compelling clinical story and translate it into something that makes a business but also ultimately helps patients.
And without sounding like Mother Teresa, that's always been an important factor to me, and it kind of is a natural transition when that, those are things that are important in your career that you move into startups. And startups give you that unique self-expression piece that allow you to really shape your own business story and your own business models and really learn from your mistakes 'cause there ain't anyone in the office next to you to blame them on, so. [laughs] Isn't that the truth? Um, we're recording this in, uh, in, in Q2 of '26, but it looks like based on your LinkedIn profile, which I'm looking at right here, you took on the CEO role at EchoPoint back in 2018.
Kind of late- Yeah, absolutely... 2018. So you've been, you've been at it for, you know, for, gosh, almost coming up on eight years here, right? Yeah, absolutely. Well, I mean, the company didn't get funded till '19, so it was-- I was brought in by the university to pull a business plan together. But, you know, l- like I said earlier, the thing that really always when you're looking at a new venture or something new, it's the clinical behind it. Mm. And what really impressed me about the group at University College London was you had, you know, Professor Malcolm Finley and Professor Adrien Desjardins, you know, very different backgrounds, biomedical engineer, cardiologist, but they'd come together and form this, this idea and this set of concepts and worked bloody hard about showing what they could do within the, the, the constraints of the academic system and, and that really intrigued me, and I also like them as individuals.
That's very important as well. I mean, I've said no to some very compelling technologies on the basis that I couldn't spend five minutes in the room with the people concerned. So I think there's a, there's an important thing when you're looking at these as a, as a-- whatever role you're coming in for, you know, it's gonna be tough. It's always hard. There's -- we always need money. There's always deadlines. But you've gotta be able to interact and work well with the people you're gonna be doing that with. Let's talk a little bit about EchoPoint before we kind of go back in time and learn a little bit more about, about your journey, right? Leading up to, leading up to today, but also, uh, you know, kind of your, your, your background and some, some key lessons that, uh, that you've picked up on throughout your career.
But I'm looking at the b- the website right now, which is echopointmedical.com. Just as it sounds if you're listening to this, echo, E-C-H-O, and then pointmedical.com. We'll link to it in the full writeup on MedSider. Let, let's pretend that I, I know nothing about the technology. I haven't researched it at all. Give me a sense for kind of what this is and how, uh, an interventional cardiologist would use this in the cath lab. The core technology's based around sensor platform, which is, which is much broader, but essentially we address something called complete physiology. There's a huge issue with people who go into cath labs, have the standard angiogram, and then basically they can't find any blockages of the, the epicardial or major vessels. That affects around 40% of patients. Hmm.
And there's a huge issue around undiagnosed coronary microvascular disease. It's encapsulated as a syndrome called NOCA, which is, uh, you know, just a, a way of encapsulating all the potential issues here. Mm-hmm. But women typically are five times more likely also to have NOCA, so there's a vast number of women who just cycle through the cath lab and get told, "Okay, we can't find anything wrong with you. We'll give you some medication," and, and send that lady home. So EchoPoint is based around a sensor platform that is a very, very simple way to use that sensor to detect coronary microvascular metrics, which are very well established, been very well-researched, but in a very simple, intuitive way that fits into cath lab workflow and is very easy to use.
Where I came into the story, if you like, in 2018, 2019, is this had been done on the bench and been shown to work in a number of preclinical models, but they needed that translation to the, you know, make it into a business, business proposition. So we set about, we, we built a plan. We were really lucky with our investors, Parkwalk Advisors, uh, and UCLTF, managed by Albion Capital, and we actually got the funding to basically work towards our first in human i- in the UK. It's a class three device here. It's a class two device in the US, so we had to deal with the, the regulatory issues in the UK.
But essentially, we, we got a good chunk of non-dilutive funding, which again, very important subject when you're looking at money, whatever stage [laughs] of development you're at. But, uh, that enabled us to basically do this 10-patient first in human at Barts, which is a major center in London, which has got the kind of gravitas you need at this stage. And that was a, that was a pivotal moment for us as a company. You know, there was a, there was a one thing that really stands out for me there. There, there was a, a woman who wrote to us and she, we'd had some publicity in the Financial Times, and she wrote, and she's convinced she's got an NOCA, and she said, "Can I be in the trial?"
'Cause she'd been through this whole roundabout through the hospitals and been told there was nothing wrong with her. You know, that really brought home to me that there, there are a lot of human beings who aren't getting the best deal out of this process right now, and that, and that really made it real for me. Yeah. No doubt. It's th- those types of stories that like, um, are, are the kind of the, the push that you often need, right? When things get hard in a startup, right? Hearing from- Yeah. Mm-hmm... hearing from real patients that are suffering from- Yeah... the disease or the issue that you're trying to solve for. So a real quick follow-up question before we get kinda, kinda some more, some more meatier questions.
So this microvascular disease, it sounds like it's much more frequent or prevalent than maybe most people would expect, and if I'm a patient and I'm kind of being sort of filtered around or bounced around, maybe from, you know, from certain, um, I guess department to department inside a hospital, right? No one can really figure out what I, what, what I have, and the angiogram actually doesn't look, it doesn't look like there's any issues, um, right? Maybe the echo doesn't look like, you know, there, there's any issues. But there is some of this underlying kind of microvascular problem, right? Yeah. And this is your, your catheter is, that's what it's, it's meant to do is like diagnose the flow. Yeah.
So, so it, it's, it's looking at flow. Flow is the important thing here. So basically, if you've got a, if you've got a microvascular issue, your flow is compromised, and it's those tiny vessels that feed the heart. When you have heart pain angina, a large chunk of patients who are, you know, don't have major blockages will have a, with a, will have this coronary NOCA angina with non-obstructive coronary arteries type syndrome, and it could be a m- many subsets of disease. And the, and I think the, you know, the other important part is when I started this, this, with the company, this whole area of coronary microvascular disease felt what I call as a Su- Sunday afternoon project.
It was a lot like s- something that was of academic interest and maybe, you know, to a few key cl- clinical academic centers, but it's really gone mainstream in the last two years, and, and that's changed the way people perceive us from a funding perspective. It's changed the way strategics look at us. It's changed the way, you know, just your ordinary conversations with people in the street. People are much more aware of this now. So I think, you know, I think the, the FT story was that, that, the, my kind of light bulb moment in terms of that, that whole piece. But really, the, the interest and focus on this space.
You know, when I first went to TCT, which is our big US conference, Transcatheter Therapeutics, it was getting like sort of, you know, sessions, but now it gets whole afternoons on it. Hmm. It's a very important subject. So that to me just underpins how key this area is, and what we're doing as a company is basically easy access to the information for people to make the right decisions. Hmm. You know, we're, our therapy, we're a diagnostic. You know, I remember when I first started out trying to raise money for this company [laughs] it was, and they said, "Oh, well, you, you're a diagnostic. You know, you diagnose it. What's the big deal? What do you do next?" Yeah. And I didn't always have a good answer to that.
[laughs] It was, it was, it was, you know, okay, well, you know, you might change your medication or something. But now you've got things like sinus reducers that are going, working through FDA approval in the US and approved in Europe. You've got different medications. You've got different subsets of patients. But I think the, the key thing is, you know, you now have a greater awareness. You have people who understand this is an important issue to be solved. And I always come back to, you know, people who are dismissive of diagnostics. Cancer is a, you know, until cancer had better diagnostics, you didn't get better therapies. Mm-hmm.
You know, it's, it's just a very simple equation. You've got to understand the problem before you solve it. No doubt. That's always a good sign, right? When, uh, when a certain area of med tech, right, starts out at, you know, with, you know, small little abstracts in the back corner at TCT. Yeah. Right? [laughs] And then two, three, four years later, maybe five years later, maybe it takes a little bit more time than that, then, you know, whole afternoons, uh, you know, are, are, are dedicated to, you know, this, this, this certain area. That's, uh, usually, usually means you're, you're onto something. So with that said, you touched on, on, on this just a, a, a little bit, but just to, to level set and make sure people kind of understand where, uh, where the company's at.
Recording this in early Q2 '26, for someone that's listening to this three, six months down the road, sounds like you completed your, your 10-patient first in human, and you're gearing up for some studies here in the US, correct? Well, yeah. We, we're intending to make our FDA submission this year in '26, uh, approval probably '27. And we are also, we're fortunate enough to win a place on the Heart X accelerator. Yeah. Again, not dilutive funding, very important. [laughs] And for that we actually get to work with a, a center. We're working with the Baptist Hospital in, uh, Little Rock, Arkansas, and they will be our US first in human site for our first 100 patients in the States. So- Mm...
two very exciting strands in, in this point in '26, where, you know, I'm off to Arkansas next week to, you know, in, uh, to, to meet them, uh, in person. But, uh, you know, it's always really exciting to talk to clinicians, and these are the, uh, the first US clinicians who are actually gonna use it, which is huge. Yeah. Pretty fun time after spending, you know, five, six years in kind of develop- Yeah... you know, early stage development just to kind of, kind of finally get to this point. Definitely some, some exciting, uh, kind of inflection, inflection point. So with that said, let's, um, let's spend maybe the next 20, 30 minutes kind of, you know, covering some, some key functional areas that most startups have to navigate at some point, uh, in their trajectory.
And, and maybe, maybe start out kind of taking us back to that kind of 2018, '19 timeframe when you're spinning it out of UCL. What do you think, um, y- there's a lot of, a lot of, a lot of physicians and a lot of, I, I would say academics, if you, if you will, right? That are, you know, maybe working on an idea and they, they think it should become a, a, a company. What, what do you think are some of the key things that they should understand about, you know, what that, what that looks like taking a, you know, a, a concept inside an academic institution and actually turning that into a, you know, a real, a real thing that clinicians can actually use in a, you know, in a first in human study?
Well, I mean, you know, I think the one thing I always like to see, uh, and I've done this four or five times now, is academics who actually talk to clinicians. Mm-hmm. You know [laughs] so they've had some kind of conversation with a, with a clinician about, "Well, I've got this idea. Do you think it has some kind of merit, and how would you use it?" You know, that, that to me says the academics kind of thought, "Well, okay, I may have a great idea, but it's got to have some kind of utility." The, the challenge is always with academia is their priorities are different. You know? Mm. They, they're under pressure to write papers, you know, produce results. Some of them are still teaching.
Da, da, da, da, da, and all the rest of it. So, so, you know, I have huge sympathy for them in the sense that they, their, their agenda is different. But if they're serious about something they think is gonna be clinically game changing, you need to talk to a clinician, and that's what attracted me to EchoPoint. The other challenge when you're, when you're translating something scientific into a clinical device, and I've seen this happen to me several times, is, you know, you can take... You know, we had a wonderful box with wires coming out of it, which was our first console [laughs] in UCL, which looked like something from the Frankenstein's lab.
You know, when you move that into an environment where you're, you know, testing it rigorously, you're providing, you know, with, you know, you're looking for ground truth, things change. You know, you find things out that weren't important to the academic. And, you know, the IP that we got from the university was, was good basic ground IP, and we've got grant patents in that space but, you know, we've had to really translate that into something that is reproducible, and you can make at a reasonable price, and produces clinically meaningful data.
Mm. So that's always the challenge is, is just that academics' priorities aren't, aren't the same. You sometimes come ag- You know, I was very lucky. I had a, a, a top-class academic in Adrian, and I had a, an, uh, a clinician in Malcolm. They're both very clever guys, but they, you know, they, they'd thought about this beforehand. Uh, but I, you know, I've been in lots of conversations where you realize this guy's very passionate about what he does, the academic, but he's not really thought through the practicalities of either making it or how it might be used in clinical practice.
So, you know, I think that translation piece is, is not about technology, it's about that understanding of the, of the hospital environment and how it works and, you know, all the usual things. You know, I, I used to work with Imperial and do a, a guest lecture spot there for, for entrepreneurs as well in their units. You know, they would say, "Well, what's the biggest unknown?" It's always regulatory. Regulatory [laughs] is just the biggest unknown. So all those things are things academics have to realize, and it's not a... You know, there's no single answer. And the other point about academics is, you know, they have to be able to admit their baby's ugly sometimes. Mm-hmm. You know? It's, it's not g- it's not gonna be perfect. Easier said than done, right? Yeah.
[laughs] Because a lot of these, a lot of these academics have been thinking about this, this idea for a long time. Right. And it's, uh... Not to under, uh, you know, under- under appreciate kind of the, the, the work there, but it's, it's, you know, they think maybe it doesn't have a lot of flaws. Yeah. And in reality, it, it has some flaws. [laughs] You know, there's some gaps to- Absolutely... and so forth. Yeah. Uh, [laughs] but you, you, you rattled off like, uh, uh, several, several things that I just wanna, I wanna emphasize. Like, if you're, um, if you're coming into a project and it's largely still stuck, I don't wanna say stuck, that's probably a poor way to describe it, but it's largely still kind of in the hands of an academic. Mm. And there's been no clinician involvement, like that's- Yeah... you know, that's probably something that should be addressed, like, sooner rather than later, because- Absolutely...
there's gonna be a lot of things that probably surface as, you know, this, this idea. Even if it's a great idea, like, you know, after, after getting it in the hands of, of someone who sees patients on a regular basis, right? That, you know, that, that idea might, might evolve a bit, right? So like that, I think that's, that's something that, you know, really important that you, uh, that you mentioned. For those that have never taken an idea out of an academic s- uh, center, what, what's a good timeline? You know, in terms of actually spinning, like taking that IP, getting the licensing deal done, and whatever kind of, like, structure that looks like. You know- Yeah... what, what do you typically kind of bake into that, that, uh, process? I got involved in the, the EchoPoint, so I'll just take that as my nearest example.
So I got involved, yeah, sort of back end of '18 and, you know, it, it took us about At that point, nine months really. Mm-hmm. Um, it wasn't like I was approaching it totally cold. There had been some discussions before, so if you add another three months on for that, it- Yeah... it's probably about a year. Okay. Um, you know, it'll really depend on your, the tech transfer people you're dealing with and things of that kind and, and, and how, you know, nifty and professional they are as well. And I think they, you know, if you, if you really wanna get it done, you'll, you'll get it done. And it's...
I think when everyone's pointed in the right direction and you, and you can kind of tick off all the, all the things you need, the license and the, the, the diligence and all the rest of it, you should be able to do that in less than a year, I would have thought. Yeah. It, it just depends. If, if there are complications about the IP, that, that can lengthen things hugely, so... But generally at that stage you've got one very discreet block of IP, you hope, and there's nothing weird about it. Yeah. So ni- nine to 12 months. Maybe a little bit faster depending on the, the center, but maybe a little bit longer, right? Depending on kind of- Yeah, absolutely... yeah, if you're dealing with a, uh, a tech transfer office that maybe doesn't do this a lot or doesn't have a refined process.
The other thing that I think is, is worth, worth kind of, um, emphasizing again that you mentioned is, like those early alpha prototypes, right? They, they are, they're often, like, really ugly. Uh, you know- Yeah, they are... and kind of like, you know, again, kind of going back to this idea of this, this concept that's been sort of like iterated upon in someone's head in an academic center, and then actually building it are two vastly different things. And it, it reminds me, I, I, uh, I posted this on, um, on LinkedIn just, uh, was it last week, I think? It was a quote from Dr. Steve, uh, Michealsen with, um, you know, he's the founder of Ferropulse. Now he's working on Field Medical. Mm-hmm. And he mentioned, like, the very, the, the very first, like, console that he, he built for that, that device, like, I mean, he, he, he almost thought he was gonna electrocute himself, right? When he first turned it on.
I mean, that's how early it, it was. And most people think of, like, Ferropulse as this, you know, phenomenal success story, which it is, and don't, don't get me wrong. But, like, in the very early days, it is, like, wires coming out of everything. It's like, I mean, it's like these are, like, [laughs] the bare bones, bare bones- Yeah. You get-... you know, sort of, I, I call it a device, but you know, pr- prototype just to s- just to answer a few basic questions, right? In those, those earliest versions. Yeah. We, we preserved ours for the EchoPoint Museum, if that ever gets [laughs] We, we laugh, but th- those are actually, those are, um, I always encourage other entrepreneurs to, like, you know, make sure you take lots of pictures of that stuff, 'cause it's always fun- Yeah...
to kind of point, point back to, especially if you run into, like, some challenging times, to think about, like, what you already overcame, you know, uh, along the journey. So, uh, with that said, let's talk a little bit about ClinReg. And you mentioned the, the first-in-human study at Barts, which is, um, obviously a very highly respected, you know, academic center. That's interesting, because I think most people, especially with a novel technology like this, would maybe go to some other, whether it's Eastern Europe, right? Or, uh, maybe somewhere in Central or South America, or kind of name your kind of classic first-in-human geography. But you chose, you chose Barts. Like, what was the kind of the rationale and for that? Yeah.
I mean, I think, I think, you know, I've done that route. You know- Mm-hmm... I've taken a, taken a sort of, you know, um, you know, less rigorous maybe initial route for those types of things. I think, you know, we had an in to Barts because Barts has been very supportive. That's where, uh, Malcolm worked. Mm-hmm. Uh, he was a cardiologist there. I've met with, uh, Professor Anthony Mathur several times as part of the process of spinning out the company and post spin-out. Uh, and he's always been very supportive. And I think they, they were very helpful in connecting us with the, you know, the major issue with any clinical trial is the administration. [laughs] And the NHS is absolutely no exception to that.
But, you know, I think they gave us the support we needed and the help we needed, and it always takes longer than you'd like. You know, I have, I, I don't think I've ever met a CEO in my life who said, "Oh, yeah, that went perfectly and on schedule." [laughs] You know? And so, so that piece worked. We also had a really good regs team in place who was working with us at EchoPoint, and from the MHRA point of view, so that piece was kind of covered off. So it made sense from a logistical point of view as much as any. You know, it, it's, it's great going to these far-flung places and, and there are a lot of great clinicians there, but just setting up a trial in a foreign country is no small p- thing. Mm-hmm.
You know, you lose a lot, you know. So we could get on the tube and go to see Barts, [laughs] you know. [laughs] And we could, we could work out, you know, and we could go and talk to clinicians, and we, we could understand, you know, and we were there at every procedure. So, you know, I think that that closeness to that first human experience in the clinic is really important. You find out so much. Mm-hmm. And I'm very precious with clinical feedback. To me, all the things you learn, even when you're not doing, you know, a trial from clinicians, are really, really important.
Uh, and we store those things at EchoPoint, and we, and we, we bank them up, and we, and we try and remember them at the right times- Mm-hmm... by bringing them into our conversations with, you know, what we're gonna do design wise, blah, blah, blah. But, you know, I think the, you know, that first in human is so important. You know- Mm-hmm... seeing it in clinical hands being used on an actual patient is so important. You know, I wouldn't want to be having, you know, have a three-hour flight to get to where that was done, you know? Yeah. It, it, to me, we wanted, you know, to be close to it and understand it. Now, the other side of that coin is, and, and I've also done this, I made this mistake in my life. I've got too close to a, a clinical center. Mm.
You end up with groupthink with your clinicians. Mm. You know? [laughs] And that is also dangerous. So you have to maintain the appropriate distance 'cause they've got a job to do, you've got a job to do. But, you know, if you start believing in each other's propaganda, then that doesn't work either, 'cause you're there to learn. Yeah. You know, a- and that's, that's also an important point, is that distance has to be there as well. So, you know, Barts was a great choice. You know, we'd loved to done it quicker. It didn't happen that way, but, you know, we got it done. We got the result we wanted. We got the information we wanted, and I think that, to me, justified Picking a heavier weight center.
And it also helped with fundraising post that. Yeah. Yeah, especially to have, to have such a premier institution kind of, uh, be involved in that, in that first human study. That, that, your, your point about, um, not believing, you know, sort of your own propaganda, right? Like, that's such a crucial point. And we, I don't talk about it enough on this program, but, like, it's, it's so crucial in those early days. You, you obviously you want physicians that are supportive of what you're doing, but if you get, like, if there's no disagreement, right? If there's no pushback, that's usually not a, a, a good sign. I mean, you want, you want some, I don't want to say haters. But you want, you know, some, a little bit of, little, some cynics, right?
That are gonna challenge some assumptions, challenge the way you're thinking about that. I think that's, like, just very, very healthy, especially in those early, those early phases. I, I worked in marketing in my early career and, you know, I, I was a product manager at J&J. And, you know, the first thing they do when there was a product complaint is drop the product manager in there. So you're, you're like, you'll be in front of some clinician who's saying, "Your product is the worst thing I ever used in my life." [laughs] Yeah. So you, you know, you begin to understand that the world isn't full of people who love j- love your company, and [laughs]- Mm-hmm... what you do. And it's the same in a startup. It's- Yeah...
you know, you've got to listen, as you say, to the other side of the story. And, and, and, you know, be aware that's something, you know, whoever you're gonna end up working with is gonna have to deal with as well, you know? Yep. Yep. You know, in the, in those early days when you're, when you're just looking for any sort of momentum, right? Um, sometimes it can be challenging because if you do have those physicians that are, uh, pressing into some, some certain things, um, it can kind of feel like, yay, they're not on your side. But it's, it's, it's usually it's a good, it's a good thing, especially if you're working with physicians that have been around startups and they know, you know, they know not to push too hard, but they know, they know to challenge certain things, you know?
Yeah. And so I think that's such, such a, such a crucial point. The other thing that you just mentioned about balancing, you know, going to a site in Eastern Europe as an example, right? Versus, you know, s- uh, a site like Barts or maybe, maybe it's a, you know, a larger institution in the US as an example. There's always trade-offs and, and, and your point about, like, um, the lift required to just get any study up and running, it, it's never easy. You know what I mean? Uh [laughs] it, it sounds easy to say, "Oh, ethics review is 30 days or 60 days, and it'll fly through." But it's like, well, there's a lot of work to build out that investigational brochure, et cetera.
So, like, don't underappreciate just the sheer amount of work regardless [laughs] of where, of where you go. Yeah. And, and it sounds like you, you had a, you had sort of some inroads into Barts already, and you sort of le- leaned into that, and it was worth kind of like some of the, um, maybe some of the, the downsides in terms of maybe length, lengthier time or cost or et cetera with doing a, doing a study there. Yeah. Yeah. Absolutely. Yeah. Really good points. One other quick question before we get to, uh, to fundraising and, and really just kind of like capital allocation in general, that, that, that topic. You're now transitioning to, to, to the US, right?
You've got this FDA submission that you're, that you're planning on, and, and you're gonna, sounds like you're gonna do this, um, this study, you know, starting out with your, your first site in, um, in, in Arkansas. What were maybe some of the meaningful things that, that you, you felt like needed to be nailed down before you sort of made that, made that transition to, to the US? [upbeat music] Hey, everyone. Let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO. We're developing next generation intravascular lithotripsy or IVL systems to tackle complex calcific disease. Over the last few years, we've closed a series of oversubscribed funding rounds, bringing the total investment into Fast Wave to over $50 million.
Corporate interest in the IVL space is growing too, the $900 million acquisition of Bolt Medical by Boston Scientific in 2025, and Johnson & Johnson's $13 billion acquisition of Shockwave Medical signal a lot of attention on emerging IVL startups like Fast Wave, and we're making serious progress. In addition to recently receiving our ninth patent, we've successfully completed peripheral and coronary feasibility studies and are gearing up for pivotal trials. If you're interested in investing in the fast-growing IVL market, head over to fastwavemedical.com/invest. Again, that's fastwavemedical.com/invest. Now let's get back to the conversation.
Oh, I mean, I think, I think it was the, the Q subs of the FDA were critical. And I think, you know, one of the, you know, my last company, I was, we were, that company spanned the change over to MDR in Europe. Mm-hmm. So we saw, you know, CE Mark being the first choice of both US and European companies to being the last choice [laughs] of US and European companies, particularly startups. So, so, you know, I think the FDA, for me, it's kind of a no-brainer 'cause it's a class two device in the United States. It's a class three device here in Europe.
And, and I think the other thing that the FDA, you know, for all the fact it's a big organization, and it can be kind of scary for, particularly for a small company, you know, you do have this ability to interact with it. Mm-hmm. And I think that's so critical. You learn so much by interacting early with the FDA. And, you know, generally they'll give you pretty straight answers to the questions you want. So, you know, I think everyone kind of, you know, sees, you know, particularly when you're sitting this side of the Atlantic, it, it's a kind of a big step and a big leap to do that. But actually, you don't have that capacity really with, with notified bodies or any of the, of the, of the, you know...
The MHRA has a scientific advisory group and, you know, I've not used it personally, but it, it, it exists. But it isn't as a, you know, clear and unambiguous as the FDA is. And I think, you know, for all its, you know, ups and downs and political pressures and all the rest of it, the FDA is a great institution that's really kind of, you know, it thinks about small companies as well as big companies. Mm-hmm. And I think that, that's really critical. You know, sometimes when you're dealing with monolithic organizations, the NHS is a good example, they don't have, they have a one size fits all, and it's great if you're AbbVie or Gilead, but, you know, [laughs] if you're, you know [laughs] then, then you, you've, you've got a gap to bridge there.
So, but no system's perfect. But I think our regulatory pathway at 510[k], we did a Q sub, we confirmed what they wanted to see. We've done subsequent Q sub to actually, yeah, refine that. And it's about just reducing risk, and that's what investors want to see as well. Mm-hmm. So, so that's, it's, it's about managing the risk in your organization and understanding You know, going to the US, you know, it's a big market, but there's also many more competitors over there, and it's- Yeah... more challenging. You've got reimbursement, da, da, da, da. But at the end of the day, it's still a huge market and a huge opportunity, and the FDA is the gate to that. Yeah.
Y- you mentioned, um, de-risking, and I think that's such a, such a crucial point because, um, if you're... Let's say you're pitching an investor, right? And, um, you get questions around sort of the regulatory process or how a certain regulatory body, c- you know, FDA as an example, is thinking about your technology, especially if it's novel, if it's, it's, you know, pr- pretty, a pretty new category, and you've not done a Q-Sub. Yeah. That's usually-- I don't wanna say it's always a red flag, but it can be a red flag, right? Because it represents a little bit of risk, right? You, you may have-- You may be even working with, like, great, you know, regulatory advisors or consultants, but if there's been no interactive-- if there's been no engagement or interaction with it, with FDA, it, it can be, you know, it can s- it can signal a little bit of, a little bit of, you know, risk, you know, to a particular investor.
So I think even if-- I guess my point in kind of rambling here is that even if you feel like a Q-Sub is overkill, it may be worth just doing because, one, it could de-risk the technology and, and kind of, um, the risk, the potential risks associated with the, the regulatory pathway. But also there, there still may be some things that you learn, right? Some unexpected things you learn through that- Absolutely... through that, that Q-Sub kind of process. So really, really good points. Um, let's jump to, to, to fundraising. And I wanna ask you two questions. One, uh, one about non-dilutive funding and then the, the, the other one about dilutive funding, right? On, on the oppo- opposite, uh, side of the coin here. But let's talk about non-dilutive funding, 'cause you've had some success here, not, not just with EchoPoint, but in previous, uh, previous companies that you've been involved with.
What's your general take on, on the use of non-dilutive funding? I mean, obviously, it, it really important in, in the early days, but is your-- like, is it your goal to kinda continue to try to, to try to raise non-dilutive funding throughout sort of the, you know, the, the journey of, uh, of, of your startups? Absolutely. I th- I, I absolutely think it's critical wherever you are, you know? Mm. I think, you know, I, it, it's been a board agenda item. It's a permanent item on our board agenda. Because we have a grant tracker, we track grants. Mm. And as you evolve as a company, so we've moved out of, you know, preclinical to, you know, we've got clinical data, you know, the, the grant environment changes, but it, it doesn't go away.
It just, the requirements to do it, and it may be a bit more work to get to, you know, larger sums of money to do bigger things in the later stages of your company, but it never goes away. The, the, the grant agenda, the grant thing is really important. The other important thing about non-dilutive funding is there are lots of consultants who will come to you with like, "We've got a million things you can apply for," and all the rest of it. But you know, the most important thing [laughs] is just, just look at the grant requirements compared to what you want to do. Mm. You know?
[laughs] So, so I was involved in a previous existence in one of the old framework things, which was the, the EU funds, and the reporting was just mind-boggling. [laughs] You know? And we spent more time talking about reporting than we did about the results of the project. So, uh, you know, to me, uh, you know, I, I love it when people get great big grants and, you know, it's, it's great news and everything, but, you know, if you're small and you don't have a lot of people, you really gotta look at the effect of- Mm... the reporting burden. But just also, you know, if that grant is skewing in a way that moves you away from your commercial objectives, that's a red flag to me. Mm-hmm.
'Cause then, then you're gonna spend time and effort and focus on something that isn't gonna get you that extra couple of million dollars or whatever it is to, to do whatever you need to do. So I think the grants are, are great, uh, and I'm a huge believer in them, but I think there's a, you know, you really, really have to look carefully that you do this. Mm. And, and consultants are really good as well. You know, I've had-- I've worked with some great people in the UK, but a lot of people I've spent a lot of time talking to are just clearly, they're trying to get you to sign some kind of retainer and ba-boom, they, they're off.
And it, and it's never, you know-- And I w- the other red flag for me is if it's never su- if it's always never success based, you know? [laughs] Whoever you're working with should have the skin in the game with you- Yeah... in terms of whether this is gonna work or not. Um- Yeah. No... so, so I, you know, I think, you know, we, we were very lucky. We raised 1.7 in pound, million pounds in, in equity, and we raised approximately a similar amount in non-dilutive funding at the beginning, and that got us to a lot of goals, uh, you know, including the first in human. So, you know, it was, it was, it was great.
And you know, as we've gone on, you know, we, we've kept applying and we, we made some small scores with that one, but you know, it's just one of those things that I think it should be there all the time. Mm. Don't ever underestimate how much, you know, if it's gonna divert you from what your investors want you to do, that, that's-- you gotta think carefully about that one. Yeah. So critical, 'cause if you ever make a, a, a significant pivot and you're left with, you know, going down this, this, the, the old legacy path, right? Because of this grant funding that you, uh, that, that you took- Yeah... you know, years ago, that could be, you know, pretty detrimental to the company.
But, but your, your, your point about, like, just the, the, the requirements I think is so, so critical, right? Because you could end up getting a, a million dollar grant, right? But now you're stuck reporting almost as if you're a publicly listed company, you know? [laughs] And it's like you've got these, these ankle weights just tied to you now moving forward. So, like, those are just, like, really, really, really good points to kinda be, be, be aware of. Let, let's talk a little bit about dilutive funding, right? Like traditional kind of, you know, fundraising from a, you know, whether it's from a family office or angels or, or venture, venture funding. You've done a lot of this, uh, throughout your career.
How you go about fundraising now, like, what, what do you-- I guess, what are, what are some of the key things that you, you, you, you kind of fully understand that you maybe didn't appreciate, you know, 10, 10 years ago when you were first, uh, maybe, maybe, uh, you know, trying to, trying to pitch, uh, investors? You know, I think one of the things is can you work with that investor, I think is a really important thing. And, and that's not, you know, that, that's not in some utopian world where there are people thrusting checks on you and you've gotta say, "I like you, but I don't like you." I think, you know, you, you pretty much find out when you're in that first pitch, whether they're, they're asking questions that are intelligent, you know, and, and they, they can be challenging and difficult and you may not be able to answer them all, but that you get a pretty- Feel that, that is somebody I feel I can work with.
So that, that I think is an important piece I've learned over the years. I think also if you're in early stage med tech, a lot of the time you're pitching in, in, you know, maybe in smaller funds, they may, they may not have specialists in your space. Mm. And, and this, this, I've seen it because I've been on the receiving end of it in, in, you know, been on panels and stuff where, you know, people have great ideas, they're a great CEO, they clearly have a good team, but they make assumptions about what you know and about the space that are totally inappropriate.
Mm. And, and, and just remember, you may be pitching to generalists. You may be pitching to people who don't understand the med tech space. And that doesn't mean say, you have to get all silly about it and take them back to the, the ABCs. [laughs] But just maintain it at a pace that's, that, that's appropriate. So what I've l- really learned is the other point about rejection, and I've had plenty of those, is try and learn something from it. Mm. Um, also don't beat your head against the wall saying, "What did I do wrong?" And keep going back to them saying, "If I change that, would that make a difference?" 'Cause generally once they've said no, that's, that's the end of the conversation. But it's also true, you know, never close a door.
You know- Mm... never, you know, somebody said no at one point, funds change, people change in charge of the funds, and funds priorities change. You know, I won't go through the obvious stuff that you see on every panel on fundraising, which is check they've got cash and all the rest of it. [laughs] That one's like as a given. But, you know, I think, I think the, the key thing is really don't be in a position where, you know, you, you storm out of the room and slam the door behind you. That, that, you know, if somebody says no, that's, that's, it's not a good way to end it. I think it's, in my younger days I got very angry when I said- [laughs]...
they, they, they seem to say, "Yeah, we love this, we love this, we love this," and you get this two-line email saying, "Sorry, we decided not to pursue this any further." That's all the feedback you get, and that's, you know, that's never gonna change, you know. Yeah. You get some funds which are great at feedback, but you know, when somebody won't give you a real reason, that, that's annoying. But hey-ho, you know. Yeah. Take it on the chin. Live with it. Learn from it if you can, if they've given you any feedback to learn from. But you know, I think the, the one piece of advice I'd give is just, you know, it is a tough environment. It's, it's toughest I've ever known it right now. Mm. But I think if you've got a good idea and you keep knocking on the doors, it's just, it's just keeping it up. And it, and it is wearing, you know. Mm-hmm.
I, I, you know, I, I've gone from CEO jobs where you raise some money and you get the chance to go and put your effort into the program. But you know, I feel like I'm on a permanent fundraising treadmill now. Mm-hmm. So, and that's just the nature of the job. The job's changed. Yeah. There's no doubt the concept of like a- always be capitalizing or always be raising, it's very true. And you know, and, and some- sometimes those, those stretches are, you know, you're, you're actively like closing a round. But other, others you're just, you're simply like, you know, meeting new investors, right? Mm. And kind of trying to, trying to grease the skids for maybe a, a future, a future round.
But your point around, um, like investor feedback, that can be, I mean it's, it's, it's easy to say, a lot harder to take when you're in the throes of facing all of those rejections. You know, all of those nos over and over and over again. And I think it's such a, it's such a, I just wanna like really [laughs] really emphasize that point, and I'm, I'm nodding in agreement of like, it can feel really challenging to hear no after no. But it's usually a no now, right? It could be a, it could be a, a maybe or a yes down the road. And so I think that's just healthy to keep in mind. If you get a no and, and maybe it, the no doesn't even come with any helpful feedback, just consider that a potential prospect down the road, right?
Put them into some sort of like, you know, potential investor update, right? That you check in it, check in with on a quarterly basis, something like that. I mean, there's always something that you can kinda glean from it. At least it's, it's a conversation. They at least know you. They know kinda what you're building. And maybe it's just consistent follow-up over the course of, you know, three, six, nine, 12 months where boom, things change with that fund, whatever, and they, the, you know, the door, the door's back open again, right? So, um, I think that's, that's, uh, a lot of times the only thing that you can kinda take with you [laughs] after getting a, getting a no and, uh, and not really getting a lot of, a lot of helpful feedback along the way.
But, um, yeah. That's, yeah, real- re- really good advice. But if you're, if you're ra- if you're listening to this or reading this interview, you know, uh, uh, and you're, you're raising capital, just know it's, it's never, it's never easy. Like, it's, uh, even if you've done it a lot before- No... it is, it is challenging to say the least. So with that said, let's, let's, uh, let's maybe end the, end the, end the discussion talking about kinda just CEO perspectives and, and, and learnings. And I wanna start maybe at, at, at the, at the board level, right? 'Cause you've been around, you, you've been on boards, you've been around a lot of startups, you know, especially over the past, you know, 10 to 15 years. What do you think are, are things that any CEO needs to really get right to try to establish some sort of like healthy function at the board level?
Well, I think, you know, when you really start out, you know, when from the get-go, you're gonna have a heavy preponderance of investors on your board. There's, there's, there's no way you're gonna escape that, because they wanna see how their money's being deployed. [laughs] So, so you just have to accept that as a given. Now, investors are investors. They're generally finance people. They won't understand your space in any technical depth. So from a, a CEO point of view, it's making sure that you're reporting in a way that they understand. But also, you know, I think w- one of the other things is, is, you know, just understand that they, they're looking at it this from, you know, "Is my money being deployed in the way I originally intended it to?" Mm-hmm.
And if they're getting uncomfortable with something that's happening, you deal with it. You know? You deal with it. I remember, you know, one of the piece of advice I, I was given very early on is if there's something, you know, horrible happened [laughs] Mm... don't bury it at the back of the board agenda. Mm. Deal with it up front. Mm. You know? A- and if I could give one piece of advice to CEOs in the, in, in a position, there's, there's, you know, if you've got some bad news, don't try and hide it- Mm... 'cause they'll find it. You know? Yeah. They, they've done this lots of times, and it'll just come back and bite you in the leg at some point.
So I think the, the point is, you know, just be upfront with them and they'll be upfront with you, and be clear with them about what you're doing. I think the other thing about, you know, information flow is you control that as CEO. So like I say, it's a power and responsibility and you've gotta make sure it's worked. Member, board members are there about strategy. Yeah, that's the other thing I've seen too many times is, you know, you're the executive, you're executing what the strategy is, and their, their role is to work with that. Anything that st- where they start trying to run the company with you, that is a huge red flag for me. [laughs] You know, I, you know, I- it's when I see...
I, I remember seeing a startup once at a university in the UK, and the, the board meetings ran for two days, and I thought, "What on earth have they got to talk about [laughs] for two days?" [laughs] You know, I mean, they run major corporates in less time. [laughs] It was because they were going through the operational plan line by line. And you're not CEO at that point. You become a kind of glorified, you know- Yeah, mm-hmm... wage taker. So, you know, I think understanding your roles in the board's important. And also, you know, very early on who your chair is. And a- any time your, who your chair is, is very important. But very early on it's very important.
You know, I, I've, my last couple of roles I've been an exec chair very early on, whereas I've done both roles, you know, 'cause it, they didn't have a separate person to do it. One of the things I do insist on is those roles are split as soon as it's practical to do so. Mm. Because that, that gives you somebody in the board who you can sound off and you can, you can kind of learn from, hopefully, if they're, if they're the right type of individual. And I've been very lucky with my current board because we've got, we've got Nancy Briefs, who's a, a US-based person. But as CEO, they, when we said we're gonna recruit a chair, I had a huge amount to say about what kind of individual I wanted. Mm.
You know, and we ran a process, and everybody interviewed them, so it wasn't like I picked them. But, you know, I think that kind of awareness from your board as to how important that relationship is, is, is key. Yeah. You know, and have someone parachuted on you is sometimes very challenging. I've had that happen before, and it's, it's never, touch wood, gone wrong. But- Right... that's more challenging when the investors say, "We want X." [laughs] Yeah. And you get no say in the matter. Yeah. You're... I can... 'Cause I think a lot of, a lot of folks maybe look at, when they look at a board and they, they see that executive, that executive chairman or the chairman role, that, you know, the natural question is, like, is that really needed, right?
What is that person really doing? But, but, but to your point, especially if, if you walk into a scenario where maybe there's an existing board or there's already some red flags- Mm... that could maybe, that could maybe be the best move, is to really, like, propose, "Let's get a, let's get a chairman," right? That can kinda serve as that, that ringleader of sorts, right? And that, that, that may be worth the cost, right? Whether it's in the form of equity or, you know, whatever compensation that executive or that chairman role c- uh, person, they can, they can play. That could be, like... That, that might be the smartest move if you're dealing with some interesting board dynamics, right? It does, it serves as a bit of, a bit of a third party, right?
An experienced third party that other folks can vent to, you know, uh, to try to help solve, help solve some difficult, difficult, uh, challenges. Yeah. That's really, really good stuff. One other, one other quick follow-up question, just thinking about your experiences and what you're bringing into EchoPoint, right? Like, maybe, maybe come, come back to, like, 2018, '19 timeframe. You've been around a lot of startups, led startups before. Is there, like, one or two things that, like, you know, you realize now, like, "Oh," like, "I'm glad I doubled down on that one or, those one or two things that really, like, that, that really mattered," right?
"That I learned from other experiences at other, other startups." Yeah, I mean, I, I think, you know, particularly at early stage where you're setting the company up is getting your relationship with the academic institution right. Mm. Essentially, you're in the position when you s- when you're spinning a company out of a university where they have all the knowledge, they have all the expertise, they, everything is sitting inside their building. And, you know, one of the keys to our advising it is w- one of your roles as, of CEO is to, is make sure you can work with that academic institution, 'cause not everyone's gonna work for you.
[laughs] You, you can be dealing with departments or people who, who are, you know, have no interest in you succeeding whatsoever. But what your role of CEO is to take all the bits of knowledge you need out of that institution and put it in your company- Mm... for your series A round. Uh, and, you know, God bless it, COVID [laughs]- [laughs]... you know, happened immediately after we formed the, the, the company. And we had to learn to s- we literally just moved out of the, the building, the university building nearby, and we had to learn to stand on our own two feet very, very rapidly by fault- Mm... by default.
So, uh, you know, I think that early stage, that relationship with your, with that academic institution, 'cause it's so critical as to whether- Mm... you're gonna lose. Now, as time e- evolves, you, you're independent, you make your own, you know, blah, blah, blah, and all the rest of it. But I think from a, you know, that early stage. The other is the investors understanding about, you know, your, your recruitment strategy and, and who you're gonna bring into your team. You know, the team you build in that early stage is not gonna be the same team you're gonna have three years later. They all change.
All those people who've got that kind of, "I can do five different jobs," and, you know, "I'm good at loads of different things," you're gonna get to much people who, much more people who are kind of focused on specific areas of the operation. So, you know, as a, as an early stage CEO, you've gotta be aware that everyone in that, in your team, uh, style has a kinda shelf life. You have a shelf life as a CEO. Mm. Uh, and you've just gotta when, you've just gotta... It's, it's, it's hard, but sometimes you've gotta say, "That person doesn't fit with what I need to do now." Mm.
So those early decisions you make based on the information you have at the time, but just be aware that changes over time. Yeah. And, and it, it, you know, trying to keep things in stasis with exactly the same team you spun out with generally doesn't work, you know? Yeah. Such a great point, right? Like, there's always fa- there's phases of startups, and those, typically those phases may a lot of times come with different folks, different people, right? So which is, I think, I think, healthy. So with that said, um, Anthony, let's, let's, let's, uh, shift to the, uh, the rapid-fire portion of this interview. But again, for everyone listening, echopointmedical.com is the website.
Highly encourage you to check, check out the, uh, the company and the technology. Really, really new, kind of new- new- newer or new-ish field in the world of, uh, interventional cardiology. We'll link to it in the full, the full write-up on, on MedSider, and we'll also include, um, uh, Anthony's LinkedIn profile as well. So with that said, first question, first rapid-fire question is, what's the most, uh, exciting milestone, um, over the next 12 months for, uh, for EchoPoint? So I think FDA, uh, submission is, is critical, and obviously clearance. Uh, but that first US clinical data is gonna be so great. You know, that ICOR data holds up in the US system is the moment we change gear as a company. Yeah. That's a, it's a big, big, big year. Yeah. 2026 for, uh, for EchoPoint and, uh, and, and, uh, ICOR.
So all right, uh, next, next question. Um, let's say, uh, let's, let's maybe say we're, you know, we're, we're sitting down for a drink in your neck of the woods over, over in the, over in the UK with a group of, you know, 10, 15 other med tech entrepreneurs. What's the one thing that you would, like, really drive home with that, with that group, right? That they would, they really need to get right in order to see, you know, any sort of a semblance of, of success at their, at their venture? I think, you know, you've got to appreciate... So we've managed to go a whole interview without saying AI. [laughs] Which is a major milestone in history, really. But I think over the period of the com- this company's been in existence, we've seen AI grow to be of massive importance in this space, and it's, it's actually affected the way the clinical space works as well, because we've seen non-invasive approaches to doing what we've done invasively, what we do invasively.
And I think better AI is a, is a really about understanding where, you know, patients correctly identified who need treatment. Uh, and I think see AI as an opportunity. Don't see it as a threat if you're a device company. Don't tack A- AI into everything. Uh, you know, I am detecting AI fatigue in investment community because it's, it's mentioned all the time. But I think, uh, you know, there, there's a, there's a clear opportunity there for people both, you know, beyond sorting out data sets and AI making better treatment decisions.
It's gonna help anyone who's involved in the sort of the physical end, because the last mile of this is always physical. You have to do something to a patient. You know, that's where devices live. We're in the, we're in the physical end of things, and AI is a, is a, is a, is an asset to us in different ways, depending on- Mm-hmm... where we are in that, that continuum. All right. Last question I've got for you. If we could rewind the clock maybe 20 years ago, maybe ear- earlier in your career, it's starting to, to, to ta- to take off, but, uh, you know, you, you don't, you still don't maybe know, know enough, uh, right? Or you know enough to be dangerous maybe at that point. Anything you'd whisper in the, in the, the younger, in the, the ears of the younger version of yourself? Yeah. I'd say trust, trust clinician signal earlier. Mm.
Trust the clinical signals earlier. You know, when clinicians get really excited and make polite noises at you- [laughs]... that's really important. Everything, you know, that, that should be what you use as your guide. You know, that, that everything else, you know, will come always just noise, you know? Yeah. Good feedback. Uh, Anthony O'Dell, thanks for, uh, thanks for carving out some time and really fun to learn about, uh, not only your journey, right, but also, uh, more about the technology you're building at, at EchoPoint. This has been fun. Great. Thanks very much for your time, Scott. It was nice- I'll, I'll, I'll have you hold on the line here, A- Anthony, but for everyone listening, you made it this far, appreciate your listening attention. As always, again, check out echopointmedical.com.
We'll link to it in the full write-up on MedSider. Those full write-ups, if you're new to this program, include a lot of the key takeaways and kind of, like, action items, if you will, right? Uh, lessons learned that you can take away from our, from our guests. Um, Anthony, uh, shared a lot of those this, this time around, um, for sure. So highly encourage you to check out tho- those write-ups. But thanks again for, for your listening attention, as always. Until the next episode of MedSider goes live, everyone, uh, take care. [upbeat music] Hey, it's Scott again. One quick thing before you go. You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups. But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion.
So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy. Just open your Apple Podcasts app or the podcasts app of your choice, search for our show, and scroll down to the ratings and review section. Leave your honest thoughts and hit that five-star rating if you think we're worthy. Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today. As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews.
Stay tuned for another informative episode coming at you soon. [upbeat music]
In this episode of SNL, we sat down with (https://www.linkedin.com/in/lorne-lucree-mba-3585942/)Lorne Lucree (https://www.linkedin.com/in/lorne-lucree-mba-3585942/), the founder and CEO of...
In this episode of SNL, we sat down with Marcus Mounir Hanana (https://www.linkedin.com/in/mmhanana/), CEO of (https://www.pantherls.com/)Panther Life Sciences (https://www.pantherls.com/). Panther is developing...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/brian-le-gette-8956252/)Brian Le Gette (https://www.linkedin.com/in/brian-le-gette-8956252/), co-founder and CEO of (https://ammortal.com/)Ammortal...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/tommoss/)Tom Moss (https://www.linkedin.com/in/tommoss/), co-founder and CEO of (https://signalring.com/)Vital Signals (https://signalring.com/),...
In this episode of SNL, we sat down with Dr. Dustin Freckleton (https://www.linkedin.com/in/dustinfreckleton/), founder and CEO of (https://happysleep.com/)Happy Health (https://happysleep.com/). Happy Health delivers...